Brief: Sumitomo Pharma America Says Nuvisertib (TP-3654) Gets EMA Orphan Drug Status For Treating Myelofibrosis
30/07/2025 18:36
July 30 (Reuters) - Sumitomo Pharma Co Ltd 4506.T: SUMITOMO PHARMA AMERICA ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY HAS GRANTED ORPHAN DRUG DESIGNATION TO NUVISERTIB (TP-3654) FOR THE TREATMENT OF MYELOFIBROSIS Source text: ID:nPn6fZHVpa Further company coverage: 4506.T ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)